Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery

Critical Care Medicine

Volumn 40, Issue 10, 2012, Pages 2805-2812

  Pretorius, Mias ^a   Murray, Katherine T ^a   Yu, Chang ^a   Byrne, John G ^a   Billings, Frederic T ^a   Petracek, Michael R ^a   Greelish, James P ^b   Hoff, Steven J ^a   Ball, Stephen K ^a   Mishra, Vineet ^c   Body, Simon C ^d   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Howard Hughes Medical Institute   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aldosterone; angiotensin converting enzyme inhibitors; atrial fibrillation; cardiac surgery; renal insufficiency

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELECTIVE SURGERY; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SINUS RHYTHM; STROKE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; BLOOD PRESSURE; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RAMIPRIL; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE;

EID: 84866559183     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31825b8be2     Document Type: Article

References (38)

1. Almassi GH, Schowalter T, Nicolosi AC, et al: Atrial fbrillation after cardiac surgery: A major morbid event? Ann Surg 1997; 226:501-511; discussion 511
2. Aranki S F, Shaw DP, Adams DH, et al: Predictors of atrial fbrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94:390-397 (Pubitemid 26266124)
3. Mathew JP, Fontes ML, Tudor IC, et al; Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group: A multicenter risk index for atrial fbril-lation after cardiac surgery. JAMA 2004; 291:1720-1729 (Pubitemid 38489894)
4. Mathew JP, Parks R, Savino JS, et al: Atrial fbrillation following coronary artery bypass graft surgery: Predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 1996; 276:300-306
5. Amar D, Shi W, Hogue CW Jr, et al: Clinical prediction rule for atrial fbrillation after coronary artery bypass grafting. J Am Coll Cardiol 2004; 44:1248-1253 (Pubitemid 39208880)
6. Creswell LL, Damiano RJ Jr: Postoperative atrial fbrillation: An old problem crying for new solutions. J Thorac Cardiovasc Surg 2001; 121:638-641
7. Echahidi N, Pibarot P, O'Hara G, et al: Mechanisms, prevention, and treatment of atrial fbrillation after cardiac surgery. J Am Coll Cardiol 2008; 51:793-801 (Pubitemid 351255619)
8. Patti G, Chello M, Candura D, et al: Randomized trial of atorvastatin for reduction of postoperative atrial fbrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114:1455-1461 (Pubitemid 44526999)
9. Belluzzi F, Sernesi L, Preti P, et al: Prevention of recurrent lone atrial fbrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53:24-29
10. Pedersen OD, Bagger H, Kober L, et al: Tran-dolapril reduces the incidence of atrial fbril-lation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376-380 (Pubitemid 29362407)
11. Vermes E, Tardif JC, Bourassa MG, et al: Enalapril decreases the incidence of atrial fbrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926-2931 (Pubitemid 36736634)
12. Pretorius M, Donahue BS, Yu C, et al: Plas-minogen activator inhibitor-1 as a predictor of postoperative atrial fbrillation after cardiopulmonary bypass. Circulation 2007; 116(Suppl 11):I1-I7 (Pubitemid 47480763)
13. Pretorius M, Murphey LJ, McFarlane JA, et al: Angiotensin-converting enzyme inhibition alters the fbrinolytic response to cardiopulmonary bypass. Circulation 2003; 108:3079-3083 (Pubitemid 38031795)
14. Kwapisz MM, Müller M, Schindler E, et al: The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18:53-58 (Pubitemid 38240761)
15. Miceli A, Capoun R, Fino C, et al: Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2009; 54:1778-1784
16. Sun X, Zhang L, Hill PC, et al: Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur J Cardio-thorac Surg 2008; 34:820-825
17. Sawathiparnich P, Kumar S, Vaughan DE, et al: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endo-crinol Metab 2002; 87:448-452 (Pubitemid 34158202)
18. Fleming GA, Murray KT, Yu C, et al: Milri-none use is associated with postoperative atrial fbrillation after cardiac surgery. Circulation 2008; 118:1619-1625
19. Salehian O, Healey J, Stambler B, et al; HOPE Investigators: Impact of ramipril on the incidence of atrial fbrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154:448-453 (Pubitemid 47271928)
20. Dabrowski R, Sosnowski C, Jankowska A, et al: ACE inhibitor therapy: Possible effective prevention of new-onset atrial fbrillation following cardiac surgery. Cardiol J 2007; 14:274-280
21. Rader F, Van Wagoner DR, Gillinov AM, et al: Preoperative angiotensin-blocking drug therapy is not associated with atrial fbrilla-tion after cardiac surgery. Am Heart J 2010; 160:329-336.e1
22. Shariff N, Zelenkofske S, Eid S, et al: Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fbrillation after CABG surgery. BMC Cardiovasc Disord 2010; 10:7
23. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001; 285:2719-2728 (Pubitemid 32525368)
24. Lewis EJ, Hunsicker LG, Bain R P, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462 (Pubitemid 23335891)
25. Benedetto U, Sciarretta S, Roscitano A, et al: Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. Ann Thorac Surg 2008; 86:1160-1165
26. Mangano DT, Miao Y, Vuylsteke A, et al; Investigators of The Multicenter Study of Periop-erative Ischemia Research Group; Ischemia Research and Education Foundation: Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297:471-479
27. Schneeweiss S, Seeger JD, Landon J, et al: Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358:771-783 (Pubitemid 351284455)
28. Kincaid EH, Ashburn DA, Hoyle JR, et al: Does the combination of aprotinin and angio-tensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Tho-rac Surg 2005; 80:1388-1393 (Pubitemid 41354125)
29. Mouton R, Finch D, Davies I, et al: Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: A retrospective observational study. Lancet 2008; 371:475-482 (Pubitemid 351200595)
30. Gaudino M, Andreotti F, Zamparelli R, et al. The-174G/C interleukin-6 polymorphism infuences postoperative interleukin-6 levels and postoperative atrial fbrillation. Is atrial fbrillation an infammatory complication? Circulation 2003;108(Suppl 1):II195-199. (Pubitemid 37099954)
31. Lendeckel U, Dobrev D, Goette A: Aldoste-rone-receptor antagonism as a potential therapeutic option for atrial fbrillation. Br J Pharmacol 2010; 159:1581-1583
32. Fleming GA, Billings FT 4th, Klein TM, et al: Angiotensin-converting enzyme inhibition alters the infammatory and fbrinolytic response to cardiopulmonary bypass in children. Pediatr Crit Care Med 2011; 12:532-538
33. Luther JM, Gainer JV, Murphey LJ, et al: Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48:1050-1057 (Pubitemid 44772707)
34. Ma J, Albornoz F, Yu C, et al: Differing effects of mineralocorticoid receptor-dependent and-independent potassium-sparing diuretics on fbrinolytic balance. Hypertension 2005; 46:313-320 (Pubitemid 41099163)
35. Deakin CD, Dalrymple-Hay MJ, Jones P, et al: Effects of angiotensin converting enzyme inhibition on systemic vascular resistance and vasoconstrictor requirements during hypothermic cardiopulmonary bypass. Eur J Cardiothorac Surg 1998; 13: 546-550 (Pubitemid 28273346)
36. Ali J, Chernicki W, Wood LD: Effect of furo-semide in canine low-pressure pulmonary edema. J Clin Invest 1979; 64:1494-1504
37. Wiedemann H P, Wheeler AP, Bernard GR, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Comparison of two fuid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575 (Pubitemid 43882352)
38. Farquharson CA, Struthers AD: Spirono-lactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597 (Pubitemid 30094728)